{"id":"accelerated-30-minutes-infusion","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By blocking PD-1, the drug allows the immune system to recognize and attack cancer cells more effectively. This leads to an increase in the body's immune response against cancer. The drug has been shown to be effective in treating various types of cancer.","oneSentence":"This drug works by inhibiting the PD-1 receptor, which is involved in immune suppression.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:26:33.973Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT07146360","phase":"PHASE3","title":"Efficacy and Safety Study of Proposed Biosimilar Product Reveliza vs Actilise in Patients With ST-segment Elevation Myocardial Infarction","status":"COMPLETED","sponsor":"AO GENERIUM","startDate":"2014-05-25","conditions":"Myocardial Infarction (MI)","enrollment":180},{"nctId":"NCT04832009","phase":"EARLY_PHASE1","title":"Reversing Glucose and Lipid-mediated Vascular Dysfunction","status":"RECRUITING","sponsor":"University of Kansas Medical Center","startDate":"2022-05-09","conditions":"Blood Pressure, Hypertension","enrollment":46},{"nctId":"NCT03551964","phase":"PHASE4","title":"Dual Antiplatelet Therapy For Shock Patients With Acute Myocardial Infarction","status":"COMPLETED","sponsor":"Faculty Hospital Kralovske Vinohrady","startDate":"2018-08-01","conditions":"Acute Myocardial Infarction, Cardiogenic Shock","enrollment":605},{"nctId":"NCT05681429","phase":"NA","title":"Accelerated Recovery Following Opioid-free Anaesthesia in Supratentorial Craniotomy","status":"COMPLETED","sponsor":"University of Malaya","startDate":"2023-01-01","conditions":"Opioid-Free Anaesthesia","enrollment":25},{"nctId":"NCT03818776","phase":"EARLY_PHASE1","title":"Proton Based Cardiac Sparing Accelerated Fractionated RadioTherapy in Unresectable NSCLC","status":"TERMINATED","sponsor":"Case Comprehensive Cancer Center","startDate":"2019-08-30","conditions":"Non-Small Cell Lung Cancer","enrollment":7},{"nctId":"NCT00816413","phase":"PHASE1, PHASE2","title":"Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer","status":"WITHDRAWN","sponsor":"University of Nebraska","startDate":"2008-09","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":""},{"nctId":"NCT03080311","phase":"PHASE1","title":"A Study of APG-1252 in Patients With SCLC or Other Solid Tumors","status":"COMPLETED","sponsor":"Ascentage Pharma Group Inc.","startDate":"2017-02-12","conditions":"Small Cell Lung Cancer, Solid Tumor","enrollment":50},{"nctId":"NCT03697629","phase":"PHASE2","title":"A Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Canadian Myeloma Research Group","startDate":"2018-12-03","conditions":"Multiple Myeloma in Relapse","enrollment":40},{"nctId":"NCT04887090","phase":"NA","title":"Clinical Evaluation of ADCT to Accelerate Perioperative Rehabilitation of Pneumonectomy","status":"UNKNOWN","sponsor":"Shanghai Yueyang Integrated Medicine Hospital","startDate":"2021-07","conditions":"Acupuncture Therapy, Pneumonectomy, Perioperative Period","enrollment":76},{"nctId":"NCT00003145","phase":"PHASE2","title":"Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Older Patients With Chronic Myeloid Leukemia","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"1997-08","conditions":"Accelerated Phase of Disease, Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelogenous Leukemia, BCR-ABL1 Positive","enrollment":18},{"nctId":"NCT01116232","phase":"PHASE2","title":"Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation","status":"TERMINATED","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2010-08","conditions":"Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia","enrollment":4},{"nctId":"NCT00392782","phase":"PHASE2","title":"Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2005-07","conditions":"Leukemia, Myelodysplastic Syndromes","enrollment":24},{"nctId":"NCT00281879","phase":"PHASE2","title":"Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2006-02","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":200},{"nctId":"NCT00448357","phase":"PHASE1, PHASE2","title":"Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2005-10","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":54},{"nctId":"NCT00448201","phase":"PHASE2","title":"Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2011-01-07","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":71},{"nctId":"NCT00513474","phase":"PHASE1","title":"Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2008-01","conditions":"Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia","enrollment":46},{"nctId":"NCT00683046","phase":"PHASE2","title":"T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2001-11","conditions":"Acute Myelogenous Leukemia, Lymphoid Leukemia, Chronic Myelogenous Leukemia","enrollment":204},{"nctId":"NCT01346826","phase":"PHASE4","title":"Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease (IBD)","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2011-05","conditions":"Crohn's Disease, Ulcerative Colitis","enrollment":145},{"nctId":"NCT02720614","phase":"PHASE2","title":"Hypofractionated Radiation Therapy Combined With Concurrent Chemotherapy for Patients With Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"LIN QIANG","startDate":"2012-05","conditions":"Non-small Cell Lung Cancer","enrollment":12},{"nctId":"NCT00423826","phase":"","title":"Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease","status":"NO_LONGER_AVAILABLE","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2007-01","conditions":"Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm","enrollment":""},{"nctId":"NCT00002718","phase":"PHASE2","title":"T-cell Depleted Bone Marrow and G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors in Treating Patients With Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, or Aplastic Anemia","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"1995-11","conditions":"Leukemia, Lymphoma, Myelodysplastic Syndromes","enrollment":31},{"nctId":"NCT00914914","phase":"PHASE1","title":"Safety Study of a Cell Penetrating Peptide (p28) to Treat Solid Tumors That Resist Standard Methods of Treatment","status":"COMPLETED","sponsor":"Dr. Tapas K. Das Gupta","startDate":"2009-04","conditions":"Refractory Solid Tumors","enrollment":15},{"nctId":"NCT00818961","phase":"PHASE2","title":"Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer","status":"TERMINATED","sponsor":"Northside Hospital, Inc.","startDate":"2005-05","conditions":"Leukemia, Lymphoma, Myelodysplastic Syndromes","enrollment":36},{"nctId":"NCT00782379","phase":"PHASE2","title":"Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer","status":"COMPLETED","sponsor":"Northside Hospital, Inc.","startDate":"2008-10","conditions":"Leukemia, Lymphoma, Myelodysplastic Syndromes","enrollment":20},{"nctId":"NCT00787761","phase":"PHASE2","title":"Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer","status":"COMPLETED","sponsor":"Northside Hospital, Inc.","startDate":"2007-04","conditions":"Myeloproliferative Disorders, Kidney Cancer, Leukemia","enrollment":24},{"nctId":"NCT00002833","phase":"PHASE2","title":"Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"1994-10","conditions":"Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes","enrollment":53},{"nctId":"NCT00237627","phase":"PHASE1, PHASE2","title":"Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2001-05","conditions":"Breast Cancer, Leukemia, Lymphoma","enrollment":107},{"nctId":"NCT00499499","phase":"PHASE1","title":"A Dose Escalation Study of E7107 Administered Intravenously on Days 1 and 8 Every 21 Days to Patients With Solid Tumors","status":"SUSPENDED","sponsor":"Eisai Inc.","startDate":"2007-07","conditions":"Cancer","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Infliximab (Remicade, Centocor, Malvern, Philadelphia, PA)"],"phase":"marketed","status":"active","brandName":"Accelerated 30 minutes-infusion","genericName":"Accelerated 30 minutes-infusion","companyName":"Asan Medical Center","companyId":"asan-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}